Univariable analysis of effect of clinical features on survival
| Factor . | HR . | 95% CI . | P . |
|---|---|---|---|
| Continuous age at transplant | 1.01 | 0.99-1.03 | .22 |
| Sex | |||
| Female | Reference | ||
| Male | 1.24 | 0.85-1.83 | .27 |
| WHO classification | |||
| 0 | Reference | ||
| 1 | 1.28 | 0.64-2.58 | .49 |
| 2 | 1.84 | 0.92-3.70 | .09 |
| Bone marrow blasts, % | |||
| Continuous | 1.02 | 0.99-1.06 | .19 |
| >2 | 1.77 | 1.16-2.72 | .008 |
| Hemoglobin, g/dL | 0.97 | 0.90-1.05 | .46 |
| Platelets, × 109/L | |||
| Continuous | 1.00 | 1.00-1.00 | .09 |
| ≥150 | Reference | ||
| <150 | 1.16 | 0.78-1.72 | .46 |
| Leukocytes, × 109/L (FAB) | |||
| <13 | Reference | ||
| ≥13 | 1.36 | 0.97-1.91 | .08 |
| Neutrophils, × 109/L | 1.00 | 0.98-1.02 | .95 |
| Transfusion dependency | 1.01 | 0.67-1.52 | .95 |
| Donor relation | |||
| Matched related | Reference | ||
| Matched unrelated | 0.96 | 0.62-1.48 | .86 |
| Mismatched related | 1.59 | 0.48-5.25 | .45 |
| Mismatched unrelated | 1.38 | 0.84-2.26 | .20 |
| Conditioning intensity | |||
| Myeloablative | Reference | ||
| Reduced | 1.16 | 0.83-1.65 | .37 |
| Graft type | |||
| Peripheral blood | Reference | ||
| Other | 1.68 | 0.91-3.07 | .10 |
| Pretreatment | |||
| No | Reference | ||
| Hydroxyurea | 1.02 | 0.65-1.60 | .94 |
| Hypomethylating agents | 1.13 | 0.71-1.79 | .61 |
| Other | 1.26 | 0.74-2.16 | .40 |
| Comorbidity index* | |||
| Continuous | 1.27 | 1.16-1.39 | <.001 |
| 0-1 | Reference | ||
| 2-3 | 1.44 | 0.97-2.14 | .07 |
| >3 | 2.06 | 1.35-3.15 | .001 |
| Factor . | HR . | 95% CI . | P . |
|---|---|---|---|
| Continuous age at transplant | 1.01 | 0.99-1.03 | .22 |
| Sex | |||
| Female | Reference | ||
| Male | 1.24 | 0.85-1.83 | .27 |
| WHO classification | |||
| 0 | Reference | ||
| 1 | 1.28 | 0.64-2.58 | .49 |
| 2 | 1.84 | 0.92-3.70 | .09 |
| Bone marrow blasts, % | |||
| Continuous | 1.02 | 0.99-1.06 | .19 |
| >2 | 1.77 | 1.16-2.72 | .008 |
| Hemoglobin, g/dL | 0.97 | 0.90-1.05 | .46 |
| Platelets, × 109/L | |||
| Continuous | 1.00 | 1.00-1.00 | .09 |
| ≥150 | Reference | ||
| <150 | 1.16 | 0.78-1.72 | .46 |
| Leukocytes, × 109/L (FAB) | |||
| <13 | Reference | ||
| ≥13 | 1.36 | 0.97-1.91 | .08 |
| Neutrophils, × 109/L | 1.00 | 0.98-1.02 | .95 |
| Transfusion dependency | 1.01 | 0.67-1.52 | .95 |
| Donor relation | |||
| Matched related | Reference | ||
| Matched unrelated | 0.96 | 0.62-1.48 | .86 |
| Mismatched related | 1.59 | 0.48-5.25 | .45 |
| Mismatched unrelated | 1.38 | 0.84-2.26 | .20 |
| Conditioning intensity | |||
| Myeloablative | Reference | ||
| Reduced | 1.16 | 0.83-1.65 | .37 |
| Graft type | |||
| Peripheral blood | Reference | ||
| Other | 1.68 | 0.91-3.07 | .10 |
| Pretreatment | |||
| No | Reference | ||
| Hydroxyurea | 1.02 | 0.65-1.60 | .94 |
| Hypomethylating agents | 1.13 | 0.71-1.79 | .61 |
| Other | 1.26 | 0.74-2.16 | .40 |
| Comorbidity index* | |||
| Continuous | 1.27 | 1.16-1.39 | <.001 |
| 0-1 | Reference | ||
| 2-3 | 1.44 | 0.97-2.14 | .07 |
| >3 | 2.06 | 1.35-3.15 | .001 |
As defined in Sorror et al.23